Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.120
+0.240 (+8.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 08, 2021
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7...
Via
Benzinga
Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
December 03, 2021
Lexaria Bioscience Corp. (NASDAQ:
Via
Benzinga
Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
November 29, 2021
Lexaria Bioscience Corp
Via
Benzinga
Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications
November 24, 2021
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu...
Via
Benzinga
Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs
November 18, 2021
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds...
Via
Benzinga
Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study
November 15, 2021
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,...
Via
Benzinga
Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes
November 11, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs...
Via
Benzinga
Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity
November 04, 2021
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h...
Via
Benzinga
Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
November 03, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
November 02, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“...
Via
Benzinga
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
November 01, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure...
Via
Benzinga
Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users
October 26, 2021
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver...
Via
Benzinga
Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension
September 08, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH...
Via
Benzinga
Exposures
Product Safety
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction
September 07, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented...
Via
Benzinga
Why Lexaria Bioscience Shares Are Trading Higher Today
September 07, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 07, 2021
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...
Via
Benzinga
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
September 07, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
September 02, 2021
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral...
Via
Benzinga
Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months
July 29, 2021
Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 27, 2021
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2...
Via
Benzinga
61 Biggest Movers From Yesterday
July 23, 2021
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
July 22, 2021
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating...
Via
Benzinga
21 Stocks Moving in Thursday's Pre-Market Session
July 22, 2021
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 21, 2021
Gainers Second Sight Medical (NASDAQ:EYES
Via
Benzinga
61 Biggest Movers From Yesterday
July 22, 2021
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's...
Via
Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Sleep Number Shares Slide After Q2 Results
July 21, 2021
Toward the end of trading Wednesday, the Dow traded up 0.73% to 34,765.42 while the NASDAQ rose 0.66% to 14,594.38. The S&P also rose, gaining 0.69% to 4,352.90. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 21, 2021
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3...
Via
Benzinga
Mid-Day Market Update: Crude Oil Up 4%; Chembio Diagnostics Shares Spike Higher
July 21, 2021
Midway through trading Wednesday, the Dow traded up 0.79% to 34,785.02 while the NASDAQ rose 0.59% to 14,584.15. The S&P also rose, gaining 0.70% to 4,353.50. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
38 Stocks Moving In Wednesday's Mid-Day Session
July 21, 2021
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.